236 related articles for article (PubMed ID: 26630010)
61. A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster.
Lorén CE; Englund C; Grabbe C; Hallberg B; Hunter T; Palmer RH
EMBO Rep; 2003 Aug; 4(8):781-6. PubMed ID: 12855999
[TBL] [Abstract][Full Text] [Related]
62. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
63. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Anand M; Lai R; Gelebart P
Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
[TBL] [Abstract][Full Text] [Related]
64. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
Wu F; Wang P; Zhang J; Young LC; Lai R; Li L
Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185
[TBL] [Abstract][Full Text] [Related]
65. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines.
Miyake I; Hakomori Y; Shinohara A; Gamou T; Saito M; Iwamatsu A; Sakai R
Oncogene; 2002 Aug; 21(38):5823-34. PubMed ID: 12185581
[TBL] [Abstract][Full Text] [Related]
66. Searching for Novel Anaplastic Lymphoma Kinase Inhibitors: Structure-Guided Screening of Natural Compounds for a Tyrosine Kinase Therapeutic Target in Cancers.
Adnan M; Koli S; Mohammad T; Siddiqui AJ; Patel M; Alshammari N; Bardakci F; Elasbali AM; Hassan MI
OMICS; 2022 Aug; 26(8):461-470. PubMed ID: 35925819
[TBL] [Abstract][Full Text] [Related]
67. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
[TBL] [Abstract][Full Text] [Related]
68. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
69. Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment.
Mazot P; Cazes A; Dingli F; Degoutin J; Irinopoulou T; Boutterin MC; Lombard B; Loew D; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M
PLoS One; 2012; 7(3):e33581. PubMed ID: 22479414
[TBL] [Abstract][Full Text] [Related]
70. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
71. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
[TBL] [Abstract][Full Text] [Related]
72. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.
Ambrogio C; Voena C; Manazza AD; Piva R; Riera L; Barberis L; Costa C; Tarone G; Defilippi P; Hirsch E; Boeri Erba E; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Blood; 2005 Dec; 106(12):3907-16. PubMed ID: 16105984
[TBL] [Abstract][Full Text] [Related]
73. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
[TBL] [Abstract][Full Text] [Related]
74. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.
Scarfò I; Pellegrino E; Mereu E; Kwee I; Agnelli L; Bergaggio E; Garaffo G; Vitale N; Caputo M; Machiorlatti R; Circosta P; Abate F; Barreca A; Novero D; Mathew S; Rinaldi A; Tiacci E; Serra S; Deaglio S; Neri A; Falini B; Rabadan R; Bertoni F; Inghirami G; Piva R;
Blood; 2016 Jan; 127(2):221-32. PubMed ID: 26463425
[TBL] [Abstract][Full Text] [Related]
75. Structural basis for ligand reception by anaplastic lymphoma kinase.
Li T; Stayrook SE; Tsutsui Y; Zhang J; Wang Y; Li H; Proffitt A; Krimmer SG; Ahmed M; Belliveau O; Walker IX; Mudumbi KC; Suzuki Y; Lax I; Alvarado D; Lemmon MA; Schlessinger J; Klein DE
Nature; 2021 Dec; 600(7887):148-152. PubMed ID: 34819665
[TBL] [Abstract][Full Text] [Related]
76. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion.
Englund C; Lorén CE; Grabbe C; Varshney GK; Deleuil F; Hallberg B; Palmer RH
Nature; 2003 Oct; 425(6957):512-6. PubMed ID: 14523447
[TBL] [Abstract][Full Text] [Related]
77. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
Iwahara T; Fujimoto J; Wen D; Cupples R; Bucay N; Arakawa T; Mori S; Ratzkin B; Yamamoto T
Oncogene; 1997 Jan; 14(4):439-49. PubMed ID: 9053841
[TBL] [Abstract][Full Text] [Related]
78. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.
Di Paolo D; Ambrogio C; Pastorino F; Brignole C; Martinengo C; Carosio R; Loi M; Pagnan G; Emionite L; Cilli M; Ribatti D; Allen TM; Chiarle R; Ponzoni M; Perri P
Mol Ther; 2011 Dec; 19(12):2201-12. PubMed ID: 21829174
[TBL] [Abstract][Full Text] [Related]
79. Leukocyte receptor tyrosine kinase interacts with secreted midkine to promote survival of migrating neural crest cells.
Vieceli FM; Bronner ME
Development; 2018 Oct; 145(20):. PubMed ID: 30228102
[TBL] [Abstract][Full Text] [Related]
80. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
